45 results about "Blood platelet counts" patented technology

Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal. The chimeric thrombopoietin receptor comprises either the transmembrane domain of a human thrombopoietin receptor or both the extracellular and transmembrane domains of a human thrombopoietin receptor operably coupled to a cytoplasmic domain of a non-human thrombopoietin receptor.

The invention provides a calf spleen extractive and application thereof to idiopathic thrombocytopenic purpura treatment. The preparation technology of the calf spleen extractive comprises the steps of preparation and freeze thawing of a homogenate, and pH adjustment and film filtration under the synergistic effect of combinative enzymes, as well as sterile filtering and filling. The extraction rate of polypeptide and ribose in the calf spleen extractive is greatly increased, and the glycopeptide ratio is set to be 80-87. The activity, capable of treating ITP, of the calf spleen extractive is verified through blood platelet counting and CD4<+>CD25<+>T proportion in all the immune organs, and the result shows that the calf spleen extractive can remarkably improve the blood platelet level by 50% than the original process, the hematopoietic function is improved and no toxic or side effects is generated.

The invention relates to application of ginsenoside in the pharmacy field, in particular to application of ginsenoside in preparing antiphospholipid syndrome molecular targeting treatment medicine. In a laboratory antiphospholipid syndrome mouse model, the compound can effectively lower the level of anticardiolipin antibodies, anti-beta2-GP1 antibodies and lupus anticoagulants in blood; meanwhile, in a pregnant mouse model, the compound effectively lower aCL activation, shortens partial thromboplastin time and reduces the blood platelet count and the abortion rate; safety study shows that the compound is high in safety, has no influence on the central nervous system, the cardiovascular system and the respiratory system and has no mutagenic action. It is indicated that the compound has high safety and a good inhibiting effect on the antiphospholipid syndrome at the test dose and can be used for treating the antiphospholipid syndrome.

The invention discloses a Zhuang medicine composition assisted in resisting lung cancer. The Zhuang medicine composition is characterized by being prepared from the following Zhuang medicinal materials: Nyarinngoux (Chinese name: baihuasheshecao), Gaeubwnhgauh (Chinese name: baiying), Byaekloekhauj (Chinese name: longkui), Buenqcilienz (Chinese name: banzhilian), Ginghgun (Chinese name: guangxi eshu), Fouxndoengz (Chinese name: shishangbai), Swnjgyaeujhenj (Chinese name: huanghuadaoshuilian), Raggongox (Chinese name: lugen), GO gyauhgujlanz (Chinese name: jiaogulan) and Lozhangoj (Chinese name: luohanguo). The Zhuang medicine composition is combined with chemical drugs for curing lung cancer, can reduce the toxic and side effects of inappetence caused by the chemical drugs, reduce the damage of the chemical drugs to immune organs, increase white blood cell count, blood platelet count, red blood cell count and hemoglobin count to reduce the inhibiting effect on myelosuppression, reduce the content of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase to alleviate the damage to liver functions and increase the tumor suppression function of the chemical drugs. Namely, the Zhuang medicine composition is combined with the chemical drugs for curing the lung cancer and has the effects of toxicity reducing and efficacy enhancing.

The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt / V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients.

The invention discloses a blood detection method, comprising: processing a blood sample with a first reagent to obtain a test sample, the first reagent includes a hemolytic agent, and the hemolytic agent lyses red blood cells in the blood sample into its Fragments whose light scattering properties are significantly different from platelets; make the particles in the sample to be tested pass through the detection area of ​​the optical detection system one by one, and obtain the optical information of the sample to be tested; and obtain according to at least two of the optical information Optical information of platelets. The method of the present invention obtains platelet count by lysing red blood cells in a blood sample, and can simultaneously distinguish white blood cell subgroups.